1.	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00507, E1305, CDR0000582533, U10CA021115, ECOG-E1305, NCT00588770
2.	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000675520, NCCTG-N09C6, N09C6, NCT01156142
3.	A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: J08101, CA180123, NCT00882583
4.	Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO # 06-0509, NCT00970502
5.	Preoperative Treatment With Cetuximab and/or IMC-A12 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0342, NCT00957853
6.	A Study in Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13420, I4E-MC-JXBB, NCT01063075
7.	Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0395, NCT01064479
8.	Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and ovwe Sponsor: Other Protocol IDs: FER-HN-027, NCI-2011-00272, NCT01316757
9.	Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DCA 2010, NCT01386632
10.	Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CTRC 11-36, HSC20120002H, NCT01588431
11.	Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01640, 12-1359, N01CM00071, NCT01696955
12.	Four Doses of MAGE Vaccine for Patients With Squamous Cell Carcinoma of the Head and Neck Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: HP-41372, UMGCC 0804, NCT00704041
13.	Dose-escalation Study of Oral CX-4945 Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C4-08-001, NCT00891280
14.	Sirolimus and Cetuximab in Advanced Malignancies Phase: Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2009-0226, NCT00940381
15.	MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Phase: Phase I Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000654169, UPCC-808258, 808258, NCT00984074
16.	Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: M06-10083, NCT01017185
17.	First in Man Study of SAR566658 Administered Every 3 Weeks in Patients With DS6-positive and Refractory Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TED10499, U1111-1116-4129, 2011-003891-35, NCT01156870
18.	Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ENT0031, SU-05052010-5866, 18245, NCT01163487
19.	Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC Phase: Phase I Type: Treatment Status: Active Age: 19 and over Sponsor: NCI, Other Protocol IDs: MCC 13222, NCI-2010-02340, P30CA016059, NCT01283178
20.	Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 19 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PNP-001, NCT01310179
21.	A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BP25385, 2010-021168-13, NCT01358903
22.	A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MM-121-05-01-05 (TCD11696), NCT01451632
23.	A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 115717, NCT01458067
24.	Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients Phase: Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: J11129, P50DE019032, NA_00023916, NCT01493154
25.	A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLJM716X2101, 2011-004865-33, NCT01598077